Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
-
ORGANIZATION AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
-
REGULATORY MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
-
REGULATORY TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
-
REGULATORY Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
-
REGULATORY 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
-
REGULATORY MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
-
BUSINESS Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
-
ORGANIZATION New 3 Price-Band Rule Will Boost Predictability, Foster Healthy Competition: JGA Officials
October 2, 2015
-
REGULATORY Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
-
ORGANIZATION “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
-
ORGANIZATION Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
-
REGULATORY Health Policy Bureau Chief Futagawa Tapped for MHLW’s Top Bureaucratic Post
September 28, 2015
-
BUSINESS Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
-
REGULATORY Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
-
REGULATORY One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
-
ORGANIZATION JPMA Reprimands Pfizer over Failure to Report ADRs
September 18, 2015
-
ORGANIZATION JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
-
BUSINESS RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…